A Study of Brentuximab Vedotin and Nivolumab in Relapsed or Treatment-Resistant Hodgkin Lymphoma

Alex Herrera, MD, assistant professor, City of Hope, discusses a study investigating the use of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in the treatment of relapsed or treatment-resistant Hodgkin lymphoma during the American Society of Hematology (ASH) Annual Meeting.